

Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement

Firm News | October 31, 2024

Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent \$300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors. The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Chris W. Trester](#)

[Evan Shepherd](#)

[Candice D. Johnson](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)